Evidence map›Paper›PMID 28551713›Full record

ArticlePsychopharmacology2017

Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals.

Luca Passamonti, M Luijten, H Ziauddeen, I T S Coyle-Gilchrist, T Rittman, S A E Brain, R Regenthal, I H A Franken, B J Sahakian, E T Bullmore and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Recent Advances in Attention Bias Modification for Substance Addictions.International journal of environmental research and public health · 2018
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Luca PassamontiDepartments of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0SZ, UK. lp337@medschl.cam.ac.uk.
M LuijtenBehavioural Science Institute, Radboud University, Nijmegen, Netherlands.
H ZiauddeenCambridgeshire and Peterborough Foundation Trust, Cambridge, UK.
I T S Coyle-GilchristDepartments of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0SZ, UK.
T RittmanDepartments of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0SZ, UK.
S A E BrainDepartments of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0SZ, UK.
R RegenthalDivision of Clinical Pharmacology, Rudolf-Boehm-Institute of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany.
I H A FrankenInstitute of Psychology, Erasmus University Rotterdam, Rotterdam, Netherlands.
B J SahakianBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
E T BullmoreBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
T W RobbinsBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
K D ErscheBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
University of Cambridge · GBCambridgeshire and Peterborough NHS Foundation Trust · GBErasmus University Rotterdam · NLLeipzig University · DERadboud University Nijmegen · NL

Funding

Medical Research Council G1100464Medical Research Council MR/J012084/1
6 · The paper itself

Abstract

rationaleBiased attention towards drug-related cues and reduced inhibitory control over the regulation of drug-intake characterize drug addiction. The noradrenaline system has been critically implicated in both attentional and response inhibitory processes and is directly affected by drugs such as cocaine.

objectivesWe examined the potentially beneficial effects of the noradrenaline reuptake inhibitor atomoxetine in improving cognitive control during two tasks that used cocaine- and non-cocaine-related stimuli.

methodsA double-blind, placebo-controlled, and cross-over psycho-pharmacological design was employed. A single oral dose of atomoxetine (40 mg) was administered to 28 cocaine-dependent individuals (CDIs) and 28 healthy controls. All participants performed a pictorial attentional bias task involving both cocaine- and non-cocaine-related pictures as well as a verbal go/no-go task composed of cocaine- and food-related words.

resultsAs expected, CDIs showed attentional bias to cocaine-related cues whilst controls did not. More importantly, however, atomoxetine, relative to placebo, significantly attenuated attentional bias in CDIs (F

conclusionsOur findings suggest that atomoxetine reduces attentional bias to drug-related cues in CDIs. This may result from atomoxetine's modulation of the balance between tonic/phasic activity in the locus coeruleus and the possibly parallel enhancement of noradrenergic neurotransmission within the prefrontal cortex. Studying how cognitive enhancers such as atomoxetine influence key neurocognitive indices in cocaine addiction may help to develop reliable biomarkers for patient stratification in future clinical trials.

Indexed as

CuesAdministration, OralAdrenergic Uptake InhibitorsAdultAtomoxetine HydrochlorideAttentionAttentional BiasCocaine-Related DisordersCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedPhotic StimulationPsychomotor PerformanceAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideAtomoxetineAttentional biasCocaine addictionNoradrenalineResponse inhibition

Identifiers

PMID28551713
PMCPMC5519645
OpenAlexW2619865078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.